EUCTR2016-003320-23-FR进行中（未招募）1 期
Prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study assessing the efficacy and safety of macitentan in Fontan-palliated adult and adolescent subjects. - RUBATO
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 134
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Written informed consent/assent from the subject and/or a legal representative prior to initiation of any study-mandated procedures
- •- Fontan-palliated subjects with either intra-atrial lateral tunnel total cavopulmonary connection (LT-TCPC), or extra cardiac tunnel TCPC (EC-TCPC) surgery > 1 year before Screening. Either LT- or EC-TCPC can be primary or secondary to atrio-pulmonary connection
- •- New York Heart Association (NYHA) functional class (FC) II or III (assessed by the investigator using the Specific Activity Scale
- •- Age range: >= 12 years old
- •- Women of childbearing potential must have a negative serum pregnancy test at the Randomization visit, perform monthly pregnancy tests, and use reliable contraception
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 40
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 94
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Pattern of Fontan circulation severity
- •- Deterioration of the Fontan-palliated condition
- •- Systolic BP < 90 mmHg (< 85 mmHg for < 18 years old and < 150 cm of height) at rest or during Cardiopulmonary exercise testing at screening or baseline
- •- Criteria related to macitentan use
- •- Limitations to Cardiopulmonary exercise testing (CPET)
- •- Peak VO2 < 15 mL/kg/min.
- •- Any known factor or disease that may interfere with treatment compliance or full participation in the study
研究者
相似试验
进行中（未招募）
1 期
A clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension (PAH).Pulmonary Arterial HypertensionMedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-004786-25-BGActelion Pharmaceuticals Ltd.250
进行中（未招募）
1 期
Clinical study assessing the safety and efficacy of macitentan in Fontan-palliated subjects.Congenital Heart FailureEUCTR2016-003320-23-CZActelion Pharmaceuticals Ltd134
进行中（未招募）
1 期
Clinical study assessing the safety and efficacy of macitentan in Fontan-palliated subjects.EUCTR2016-003320-23-IEActelion Pharmaceuticals Ltd134
进行中（未招募）
1 期
Clinical study assessing the safety and efficacy of macitentan in Fontan-palliated subjects.Congenital Heart FailureMedDRA version: 20.0Level: PTClassification code 10045545Term: Univentricular heartSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 21.1Level: PTClassification code 10065950Term: Cavopulmonary anastomosisSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2016-003320-23-PLActelion Pharmaceuticals Ltd134
进行中（未招募）
1 期
A clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension (PAH).Pulmonary Arterial HypertensionMedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-004786-25-DEActelion Pharmaceuticals Ltd.250